StockUS listing USOTLKNASDAQHealthcareEarnings Deterioration

OUTLOOK THERAPEUTICS INC(OTLK) Stock Analysis | Healthcare

USD --+0.00%
Reward46Moderate
Risk64Medium-High
75%Data
Revenue down 99% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 100.54M
Reward Ratingⓘ46 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ64 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on OTLK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is OUTLOOK THERAPEUTICS INC?

, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.

AI Brief Pro

The brief on OUTLOOK THERAPEUTICS INC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is OUTLOOK THERAPEUTICS INC?

, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 100.54M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap100.54M
Beta0.715
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.